
ASX Announcement and Media Release

3 August 2005

SciGen Limited

Delay in Insulin Registration in Bangladesh

On 21 June 2005 SciGen Limited ("SciGen" or the "Company") announced that it had executed a commercialization agreement with Rangs Pharmaceuticals Ltd ("Rangs") in Bangladesh for the commercialization of SciLin™.

SciGen has recently received advice from Rangs, that owing to a new policy initiative by the Government of Bangladesh, it will not be possible to register SciLin™ in the short term. Registration will be delayed until SciLin™ is registered in at least two of eight jurisdictions nominated by the Bangladesh authorities. Australia is one of those nominated.

SciGen will continue to pursue other registrations of SciLin™ in the Asia Pacific Region and in addition work with its strategic partner Bioton, in order to achieve the maximum number of registrations (and then sales) for the product.

About SciGen

SciGen Ltd is a biopharmaceutical company essentially involved in commercialising later stage research. It co-develops and markets genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which can allow for faster entry into the market, as biogeneric products have undergone much of the clinical development and trials

required to bring new drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with offices also in Australia, USA, Korea, Vietnam, Hong Kong and Philippines and partners in India, China, Indonesia, Israel, Poland and the Netherlands.

=====ENDS=====

Media enquiries

Saul Mashaal
Executive Vice Chairman, Founder and Chief Executive Officer
Telephone: +65 6779 6638
Web: www.scigen.com.au